This Week’s CGT News: New FDA Genome Editing Guidance  - Takeaway - MDSpire
Clinical Guidelines
Feature

This Week’s CGT News: New FDA Genome Editing Guidance 

Our latest roundup highlights tighter FDA expectations for genome editing safety, advances in CRISPR precision and delivery, and continued momentum for off-the-shelf CAR-T

  • April 20, 2026

  • 6 min

Share

  • 1

    FDA's guidelines stress the use of NGS in gene therapy assessments.

  • 2

    Allogene's cema-cel shows a 58.3% MRD clearance in lymphoma.

  • 3

    Long-term CAR-T follow-up may be reduced to 5 years.

  • 4

    ThermoCas9 distinguishes methylated tumor DNA.

  • 5

    AAV delivery systems are optimized by smaller CRISPR variants.

  • 6

    Mixed-affinity CAR-T combines high/low-affinity cells.

  • 7

    New CRISPR technologies enhance cancer treatment targeting.

Original Source(s)

This Week’s CGT News: New FDA Genome Editing Guidance 

  • April 20, 2026

Related Content

This Week’s Biopharma News: KRAS Breakthrough and ADC Momentum

Revolution’s KRAS breakthrough, strong ADC signals from GSK, and shifting regulatory and dealmaking dynamics define this week in biopharma

  • April 21, 2026

  • 4 min
Modeling the Genetics of Uveal Melanoma

Researchers have developed a genetically engineered mouse model that mirrors the genetic evolution of uveal melanoma

  • April 21, 2026

  • 3 min
‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?

Prostate specific antigen (PSA) screening remains one of the most controversial of “standard” medical practices. As recently as the 2026 Super Bowl, one of the more unusual TV advertisements, sponsore...